Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Oct;72(4):818–823. doi: 10.1038/bjc.1995.419

Urokinase and macrophages in tumour angiogenesis.

R Hildenbrand 1, I Dilger 1, A Hörlin 1, H J Stutte 1
PMCID: PMC2034060  PMID: 7547226

Abstract

Recent studies have shown that elevated levels of urokinase plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1) in breast cancer correlate with an increased risk of a reduced relapse-free survival time and shortened overall survival times. Urokinase PA and PAI-1 are independent prognostic indicators for breast cancer. The fact that plasminogen activators are indispensable for tube formation of microvascular cells and that they may induce angiogenesis in vitro strongly suggests a role for uPA and PAI-1 in tumour neovascularisation. Because macrophages and tumour cells produce uPA, we postulate a close collaboration between tumour cells and tumour-associated macrophages in angiogenesis. To investigate how uPA levels and macrophage counts in tumour tissue correlate with angiogenesis, we counted microvessels and determined uPA levels and macrophage content in 42 primary invasive breast carcinomas. Using light microscopy, we highlighted the vessels by staining their endothelium cells immunocytochemically for CD31 and factor VIII and the macrophages for CD68. After obtaining tumour tissue extracts, we determined the uPA and PAI-1 levels by ELISA. A positive correlation between microvessel density, vascular invasion, uPA level, macrophage content and proliferation rate was found.

Full text

PDF
818

Images in this article

819Figure 1
on p.819
819Figure 2
on p.819
822Figure 7
on p.822
822Figure 8
on p.822

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Assoian R. K., Fleurdelys B. E., Stevenson H. C., Miller P. J., Madtes D. K., Raines E. W., Ross R., Sporn M. B. Expression and secretion of type beta transforming growth factor by activated human macrophages. Proc Natl Acad Sci U S A. 1987 Sep;84(17):6020–6024. doi: 10.1073/pnas.84.17.6020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Berse B., Brown L. F., Van de Water L., Dvorak H. F., Senger D. R. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell. 1992 Feb;3(2):211–220. doi: 10.1091/mbc.3.2.211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brown L. F., Dvorak A. M., Dvorak H. F. Leaky vessels, fibrin deposition, and fibrosis: a sequence of events common to solid tumors and to many other types of disease. Am Rev Respir Dis. 1989 Oct;140(4):1104–1107. doi: 10.1164/ajrccm/140.4.1104. [DOI] [PubMed] [Google Scholar]
  4. Cordell J. L., Falini B., Erber W. N., Ghosh A. K., Abdulaziz Z., MacDonald S., Pulford K. A., Stein H., Mason D. Y. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem. 1984 Feb;32(2):219–229. doi: 10.1177/32.2.6198355. [DOI] [PubMed] [Google Scholar]
  5. Danø K., Andreasen P. A., Grøndahl-Hansen J., Kristensen P., Nielsen L. S., Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139–266. doi: 10.1016/s0065-230x(08)60028-7. [DOI] [PubMed] [Google Scholar]
  6. Falcone D. J., McCaffrey T. A., Haimovitz-Friedman A., Garcia M. Transforming growth factor-beta 1 stimulates macrophage urokinase expression and release of matrix-bound basic fibroblast growth factor. J Cell Physiol. 1993 Jun;155(3):595–605. doi: 10.1002/jcp.1041550317. [DOI] [PubMed] [Google Scholar]
  7. Falcone D. J., McCaffrey T. A., Haimovitz-Friedman A., Vergilio J. A., Nicholson A. C. Macrophage and foam cell release of matrix-bound growth factors. Role of plasminogen activation. J Biol Chem. 1993 Jun 5;268(16):11951–11958. [PubMed] [Google Scholar]
  8. Foekens J. A., Schmitt M., van Putten W. L., Peters H. A., Bontenbal M., Jänicke F., Klijn J. G. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res. 1992 Nov 1;52(21):6101–6105. [PubMed] [Google Scholar]
  9. Gelehrter T. D., Barouski-Miller P. A., Coleman P. L., Cwikel B. J. Hormonal regulation of plasminogen activator in rat hepatoma cells. Mol Cell Biochem. 1983;53-54(1-2):11–21. doi: 10.1007/BF00225243. [DOI] [PubMed] [Google Scholar]
  10. Goldfarb R. H., Liotta L. A. Proteolytic enzymes in cancer invasion and metastasis. Semin Thromb Hemost. 1986 Oct;12(4):294–307. doi: 10.1055/s-2007-1003570. [DOI] [PubMed] [Google Scholar]
  11. Grøndahl-Hansen J., Christensen I. J., Rosenquist C., Brünner N., Mouridsen H. T., Danø K., Blichert-Toft M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 1993 Jun 1;53(11):2513–2521. [PubMed] [Google Scholar]
  12. Jänicke F., Schmitt M., Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost. 1991 Jul;17(3):303–312. doi: 10.1055/s-2007-1002624. [DOI] [PubMed] [Google Scholar]
  13. Jänicke F., Schmitt M., Pache L., Ulm K., Harbeck N., Höfler H., Graeff H. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat. 1993;24(3):195–208. doi: 10.1007/BF01833260. [DOI] [PubMed] [Google Scholar]
  14. Kobayashi H., Schmitt M., Goretzki L., Chucholowski N., Calvete J., Kramer M., Günzler W. A., Jänicke F., Graeff H. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). J Biol Chem. 1991 Mar 15;266(8):5147–5152. [PubMed] [Google Scholar]
  15. Le Doussal V., Tubiana-Hulin M., Friedman S., Hacene K., Spyratos F., Brunet M. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer. 1989 Nov 1;64(9):1914–1921. doi: 10.1002/1097-0142(19891101)64:9<1914::aid-cncr2820640926>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  16. Liu H. M., Wang D. L., Liu C. Y. Interactions between fibrin, collagen and endothelial cells in angiogenesis. Adv Exp Med Biol. 1990;281:319–331. doi: 10.1007/978-1-4615-3806-6_34. [DOI] [PubMed] [Google Scholar]
  17. Mahadevan V., Hart I. R. Metastasis and angiogenesis. Acta Oncol. 1990;29(1):97–103. doi: 10.3109/02841869009089997. [DOI] [PubMed] [Google Scholar]
  18. Montesano R., Pepper M. S., Möhle-Steinlein U., Risau W., Wagner E. F., Orci L. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell. 1990 Aug 10;62(3):435–445. doi: 10.1016/0092-8674(90)90009-4. [DOI] [PubMed] [Google Scholar]
  19. Nagy J. A., Brown L. F., Senger D. R., Lanir N., Van de Water L., Dvorak A. M., Dvorak H. F. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta. 1989 Feb;948(3):305–326. doi: 10.1016/0304-419x(89)90004-8. [DOI] [PubMed] [Google Scholar]
  20. Sato Y., Okamura K., Morimoto A., Hamanaka R., Hamaguchi K., Shimada T., Ono M., Kohno K., Sakata T., Kuwano M. Indispensable role of tissue-type plasminogen activator in growth factor-dependent tube formation of human microvascular endothelial cells in vitro. Exp Cell Res. 1993 Feb;204(2):223–229. doi: 10.1006/excr.1993.1028. [DOI] [PubMed] [Google Scholar]
  21. Schmitt M., Kanayama N., Henschen A., Hollrieder A., Hafter R., Gulba D., Jänicke F., Graeff H. Elastase released from human granulocytes stimulated with N-formyl-chemotactic peptide prevents activation of tumor cell prourokinase (pro-uPA). FEBS Lett. 1989 Sep 11;255(1):83–88. doi: 10.1016/0014-5793(89)81065-8. [DOI] [PubMed] [Google Scholar]
  22. Stump D. C., Lijnen H. R., Collen D. Purification and characterization of a novel low molecular weight form of single-chain urokinase-type plasminogen activator. J Biol Chem. 1986 Dec 25;261(36):17120–17126. [PubMed] [Google Scholar]
  23. Vassalli J. D., Baccino D., Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol. 1985 Jan;100(1):86–92. doi: 10.1083/jcb.100.1.86. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. West D. C., Hampson I. N., Arnold F., Kumar S. Angiogenesis induced by degradation products of hyaluronic acid. Science. 1985 Jun 14;228(4705):1324–1326. doi: 10.1126/science.2408340. [DOI] [PubMed] [Google Scholar]
  25. West D. C., Kumar S. The effect of hyaluronate and its oligosaccharides on endothelial cell proliferation and monolayer integrity. Exp Cell Res. 1989 Jul;183(1):179–196. doi: 10.1016/0014-4827(89)90428-x. [DOI] [PubMed] [Google Scholar]
  26. Yasunaga C., Nakashima Y., Sueishi K. A role of fibrinolytic activity in angiogenesis. Quantitative assay using in vitro method. Lab Invest. 1989 Dec;61(6):698–704. [PubMed] [Google Scholar]
  27. van Netten J. P., Ashmead B. J., Parker R. L., Thornton I. G., Fletcher C., Cavers D., Coy P., Brigden M. L. Macrophage-tumor cell associations: a factor in metastasis of breast cancer? J Leukoc Biol. 1993 Oct;54(4):360–362. doi: 10.1002/jlb.54.4.360. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES